Balloon-Expandable Versus Self-expanding Transcatheter Heart Valve for Treatment of Symptomatic Native Aortic Valve Stenosis (BEST)

Inclusion Criteria

• •The study population will be comprised of all patients with severe, calcific, symptomatic aortic stenosis eligible to percutaneous transfemoral TAVI with BE or SE-valve according to the investigating center heart team.
• •Symptomatic severe aortic stenosis defined according to the current echocardiography criteria of the European Society of Cardiology guidelines2.
• •Heart team of the investigating center agrees that the patient is eligible to TAVI with BE-valve SAPIEN 3 (Edwards Lifesciences©) (or further iterations of the same family) OR TAVI with the SE-valve Evolut-R/pro (Medtronic©) (or futher iterations of the same family).
• •Heart team of the investigating center agrees that TAVI is feasible via percutaneous transfemoral approach.
• •Written informed consent to the BEST study
• •Written informed consent to the FRANCE-TAVI registy
• •All valve anatomy are authorized (bicuspid or tricuspid aortic valve)